Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.50 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 10/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8337177 | 0.85 | KDM1A (0.60) | KDM1ARCOR1ALDH1A1TSHRHTT | |
| SCHEMBL6018900 | 0.84 | ECE1 (0.66) | KDM1ARCOR1ALDH1A1TSHRHTT | |
| SCHEMBL6018674 | 0.82 | KMT2A (0.50) | KDM1ARCOR1ALDH1A1TSHRHTT | |
| SCHEMBL8334899 | 0.82 | ECE1 (0.68) | ECE1 | |
| SCHEMBL8362917 | 0.82 | ECE1 (0.68) | ECE1 | |
| SCHEMBL6018959 | 0.78 | CCR2 (0.46) | CCR2MEN1KMT2A | |
| SCHEMBL2125011 | 0.76 | CNR2 (0.50) | KDM1ARCOR1ALDH1A1TSHRHTT | |
| SCHEMBL6467410 | 0.76 | ECE1 (0.42) | KDM1ARCOR1ALDH1A1TSHRHTT | |
| SCHEMBL3844342 | 0.75 | L3MBTL1 (0.71) | ALDH1A1TSHRCCR2KMT2A | |
| SCHEMBL8362876 | 0.74 | ECE1 (0.58) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | BAYER HEALTHCARE AG (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7045544-B2 | Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2006-05-16 | — | — | US | disclosed |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | DCK, UROD, QDPR | KDM1A 2932/4885RCOR1 2039/4885ALDH1A1 592/4885 |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | ECE1, ECE2, EDNRA | KDM1A 635/4885RCOR1 2425/4885ALDH1A1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.